US007968569B2
`
`(12) United States Patent
`Zeldis
`
`(10) Patent No.:
`(45) Date of Patent:
`
`US 7,968,569 B2
`Jun. 28, 2011
`
`(54) METHODS FORTREATMENT OF MULTIPLE
`MYELOMAUSING 3-(4-AMINO-1-OXO-1,3-
`DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE
`2,6-DIONE
`
`(75) Inventor: Jerome B. Zeldis, Princeton, NJ (US)
`(73) Assignee: Celgene Corporation, Summit, NJ (US)
`
`(*) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 145 days.
`
`(21) Appl. No.: 10/438,213
`
`(22) Filed:
`
`May 15, 2003
`
`(65)
`
`Prior Publication Data
`US 2004/OO29832A1
`Feb. 12, 2004
`
`Related U.S. Application Data
`(60) Provisional application No. 60/380,842, filed on May
`17, 2002, provisional application No. 60/424,600,
`filed on Nov. 6, 2002.
`
`(51) Int. Cl.
`(2006.01)
`A6 IK3I/445
`(52) U.S. Cl. ....................................................... S14/323
`(58) Field of Classification Search .................. 514/321,
`514/323
`See application file for complete search history.
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`3,536,809 A 10/1970 AppleZweig
`3,598,123 A
`8, 1971 Zaffaroni et al.
`3,845,770 A 11/1974 Theeuwes et al.
`3,916,899 A 11/1975 Theeuwes et al.
`4,008,719 A
`2f1977 Theeuwes et al.
`4,810,643 A
`3, 1989 Souza
`4,999.291 A
`3, 1991 Souza
`5,059,595 A 10, 1991 Le Grazie
`5,073,543 A 12/1991 Marshall et al.
`5, 120,548 A
`6, 1992 McClelland et al.
`5,134,127 A
`7, 1992 Stella et al.
`5,229,496 A
`7/1993 Deeley et al.
`5,354,556 A 10/1994 Sparks et al.
`5,385,901 A
`1/1995 Kaplanet al.
`5,391,485 A
`2/1995 Deeley et al.
`5,393,870 A
`2/1995 Deeley et al.
`5,528,823. A
`6/1996 Rudy, Jr. et al.
`5,580,755 A 12/1996 Souza
`5,591,767 A
`1/1997 Mohr et al.
`5,593.990 A
`1/1997 D'Amato
`5,629,327 A
`5, 1997 D’Amato
`5,635,517 A * 6/1997 Muller et al. ................. 514,323
`5,639,476 A
`6, 1997 OShlack et al.
`5,674,533 A 10, 1997 Santus et al.
`5,698,579 A 12, 1997 Muller
`5,712.291 A
`1/1998 D'Amato
`5,731,325 A
`3/1998 Andrulis, Jr. et al.
`5,733,566 A
`3, 1998 Lewis
`5,798.368 A
`8, 1998 Muller et al.
`5,874.448 A
`2f1999 Muller et al.
`5,877,200 A
`3, 1999 Muller
`5,929,117 A
`7, 1999 Muller et al.
`5,955,476
`9, 1999 Muller et al.
`A
`
`2/2000 Muller et al.
`6,020,358 A
`6/2000 D'Amato
`6,071,948 A
`6/2000 Dyrsting et al. .................. 514.8
`6,077,822 A *
`9, 2000 D'Amato
`6,114,355 A
`6,140,346 A 10/2000 Andrulis, Jr. et al.
`6,228,879 B1
`5, 2001 Green et al.
`6,235,756 B1
`5, 2001 D'Amato
`6,281.230 B1* 8/2001 Muller et al. ................. 514,323
`6,316,471 B1
`1 1/2001 Muller et al.
`6,326,388 B1
`12/2001 Man et al.
`6,335,349 B1
`1/2002 Muller et al.
`6,380.239 B1
`4/2002 Muller et al.
`6,395,754 B1
`5, 2002 Muller et al.
`6,403,613 B1
`6/2002 Man et al.
`6,420,414 B1
`7/2002 D'Amato
`6,458,810 B1
`10/2002 Muller et al.
`6,469,045 B1
`10/2002 D'Amato
`6,476,052 B1
`1 1/2002 Muller et al.
`6,518.298 B2
`2/2003 Green et al.
`6,555,554 B2 * 4/2003 Muller et al. ................. 514,323
`6,673,828 B1
`1/2004 Green et al.
`514/323
`7,119,106 B2 * 10/2006 Muller et al. .
`514/323
`7,189,740 B2 * 3/2007 Zeldis ........
`7,393,862 B2 * 7/2008 Zeld is ........................... 514,320
`7,435,745 B2 10/2008 D'Amato
`(Continued)
`
`
`
`WO
`
`FOREIGN PATENT DOCUMENTS
`WO92, 14455
`9, 1992
`(Continued)
`
`OTHER PUBLICATIONS
`Corral et al. Immunomodulation by thalidomide and thalidomide
`analogues ... Ann. Rheum. 1999; 58; 107-13.*
`Kyle etal. (“The Application of Thalidomide in Multiple Myeloma',
`Semin Oncol. Dec. 2001; 28(6):583-7).*
`Davies et al. (“Thalidomide and immunomodulatory derivatives aug
`ment natural killer cell cytotoxicity in multiple myeloma”. Blood.
`Jul. 1, 2001;98(1):210-6).*
`Broder et al. (“Dideoxycytidine: current clinical experience and
`future prospects. A Summary.'. Am J Med. May 21,
`1990:88(5B):31S-33S).*
`Filella et al. (Cancer Detect Prey, 1996:20(1):52-6).*
`Raza et al., 2001, “Thalidomide produces transfusion independence
`in long-standing refractory anemias of patients with myelodysplatic
`syndromes.” Blood 98(4):958-965.
`(Continued)
`Primary Examiner — Frederick Krass
`Assistant Examiner — Chris E. Simmons
`(74) Attorney, Agent, or Firm — Jones Day
`
`ABSTRACT
`(57)
`Methods of treating, preventing and/or managing cancer as
`well as and diseases and disorders associated with, or char
`acterized by, undesired angiogenesis are disclosed. Specific
`methods encompass the administration of an immunomodu
`latory compound alone or in combination with a second
`active ingredient. The invention further relates to methods of
`reducing or avoiding adverse side effects associated with
`chemotherapy, radiation therapy, hormonal therapy, biologi
`cal therapy or immunotherapy which comprise the adminis
`tration of an immunomodulatory compound. Pharmaceutical
`compositions, single unit dosage forms, and kits suitable for
`use in methods of the invention are also disclosed.
`
`15 Claims, 1 Drawing Sheet
`
`ALVOGEN, Exh. 1001, p. 0001
`
`

`

`US 7,968,569 B2
`Page 2
`
`U.S. PATENT DOCUMENTS
`2001 OO18445 A1
`8/2001 Huang et al.
`2001/0022973 A1* 9/2001 Ortyl et al. .................... 424/452
`2001.00561.14 A1 12, 2001 D'Amato
`2002fOO35090 A1
`3, 2002 Zeld is et al.
`2002/0045643 A1
`4/2002 Muller et al.
`2002fOO52398 A1
`5, 2002 D'Amato
`2002.0054899 A1
`5, 2002 Zeld is
`2002fOO61923 A1
`5, 2002 D'Amato
`2002/O128228 A1
`9, 2002 HWu
`2002fO161023 A1 10, 2002 D’Amato
`2002/0173658 A1 11, 2002 Muller et al.
`2002/0183360 A1 12/2002 Muller et al.
`2003/0013739 A1
`1/2003 Masferrer et al.
`2003/0028028 A1
`2/2003 Man et al.
`2003/OO45552 A1
`3/2003 Robarge et al.
`2003, OO69428 A1
`4/2003 Muller et al.
`2003/0096841 A1
`5/2003 Robarge et al.
`2003. O139451 A1
`7/2003 Shah et al.
`2003. O144325 A1
`7/2003 Muller et al.
`2003. O181428 A1
`9, 2003 Green et al.
`2003. O187024 A1 10, 2003 D'Amato
`2003,019 1098 A1 10, 2003 D'Amato
`2003/0235909 A1 12, 2003 Hariri et al.
`2004.0029832 A1
`2/2004 Zeld is
`2004/0067953 A1* 4/2004 Stein et al. .................... 514,251
`2004/OO77685 A1
`4/2004 Figg et al.
`2004f0077686 A1
`4/2004 Dannenberg et al.
`2004/OO87546 A1
`5, 2004 Zeld is
`2004/0091455 A1
`5, 2004 Zeld is
`2004/O122052 A1
`6, 2004 Muller et al.
`2004/0147558 A1* 7/2004 Treston et al. ................ 514,323
`2004/0266809 A1 12/2004 Emanuel et al.
`2005/0049265 A1
`3f2005 Adams .......................... 514,267
`
`FOREIGN PATENT DOCUMENTS
`WO94/20085
`9, 1994
`WO98,035O2
`1, 1998
`WO 98.5417O
`12/1998
`WOO 1/70275
`9, 2001
`WOO1? 87307
`11, 2001
`WO O2/O15926
`2, 2002
`WO O2/O59 106
`8, 2002
`WO O2/O64083
`8, 2002
`WOO3O86373
`10, 2003
`
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`
`OTHER PUBLICATIONS
`Shah et al., 1999. “Synthesis and enantiomeric separation of
`2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor
`metastasis. J. Med. Chem. 42:30 14-3017.
`Shibata et al., 1995, "N-alkylphthalimides: structural requirement of
`thalidomidal action on 12-0-tetradecanoylphorbol-13-acetate-in
`duced tumor necrosis factor a production by human leukemia HL-60
`cells.” Chem. Pharm. Bull. 43(1): 177-179.
`Shimazawa et al., 1999, ''Antiangiogenic activity of tumor necrosis
`factor-alpha production regulators derived from thalidomide.” Biol.
`Pharm. Bull. 22(2):224-226.
`Rubinet al., “Principles of Cancer Treatment-l', 12 ONCO IV I, May
`2003.
`Wilen et al., 1977, Tetrahedron 33:2725.
`Wilen, 1972, Tables of Resolving Agents and Optical Resolutions,
`E.L. Eliel, ed., Univ. of Notre Dame Press, Notre Dame, IN pp. 268.
`Wolffed., 1995, Burger's Medicinal Chemistry and Drug Discovery,
`5' ed., pp. 172-178,949-982.
`Bach, 1963, "Thalidomide in Cancer Chemotherapy.” The Lancet,
`No. 1271, p. 71.
`Bach, 1963, “Studies on the Possible Anti-Neoplastic Effect of
`Thalidomide.” Acta Pathologica Et Microbiologica Scandinavica
`59:491-499.
`Chaundhry, 1966, Cancer Research, “Effect of Prednisolone and
`Thalidomide on Induced Submandibular Gland Tumors in Hamster.”
`26(part 1) 1884-86.
`DiPaolo, 1963. “Effect of Thalidomide on a Variety of Transplantable
`Tumors.” Cancer Chemotherapy Reports No. 29, p. 99-102.
`DiPaolo, 1963, “In vitro Test Systems for Cancer Chemotherapy, II.
`Correlation of in vitro Inhibition of Dehydrogenase and Growth with
`
`in vivo Inhibition of Ehrlich Asoites Tumor.” Proceedings of the
`Society for Experimental Biology & Medicine, 114:384-387.
`DiPaolo, 1964, “Thalidomide: Effects on Ehrlich Ascites Tumor
`Cells in vitro Science 144:1583.
`Mauad, 1963, "Clinical Improvements Obtained in Advanced Caner
`Patients with Treatment with Thalidomide Associated with Hor
`mones.” Anais Paulistas de Medicina e Cirurgia 86:13-40.
`Roe and Mitchley, 1963, "Thalidomide and Neoplasia” Nature
`200:1016-1017.
`thalidomide,
`2004, “VTD (Velcade,
`al.,
`Alexanian et
`dexamethasone) as primary therapy for newly-diagnosed multiple
`myeloma.” Am. Soc. Hematol. 46' Ann. Meeting Dec. 4–7, 2004.
`San Diego, CA Abstract #210.
`Anderson, 2000, "Thalidomide: Therapeutic potential in hemato
`logic malignancies.” Seminars in Hematology 37(1 Supp. 3): 1-4.
`Attal et al., 2004, “Maintenance treatment with thalidomide after
`autologous transplantation for myeloma: First analysis of a prospec
`tive randomized study of the Intergroupe Francophone du Myelome
`(IFM 99.02).” Am. Soc. Hematol. 46' Ann. Meeting Dec. 4–7, 2004,
`San Diego, CA Abstract #535.
`Bemardeschi et al., 2003, J. Exp. Clin. Cancer Res. 22(4): 129-133.
`Corral et al., 1999. “Differential cytokine modulation and T cell
`activation by two distinct classes of thalidomide analogues that are
`potent inhibitors of TNF-alpha.” J. Immunol. 163(1):380-386.
`Davies et al., 2001, “Thalidomide and immunomodulatory deriva
`tives augment natural killer cell cytotoxicity in multiple myeloma.”
`Blood 98(1):210-216.
`Dimopoulos et al., 2004, “Primary treatment with pulsed melphalan,
`dexamethasone, thalidomide (MDT) for symptomatic patients with
`multiple myeloma 275 years of age.” Am. Soc. Hematol. 46' Ann.
`Meeting Dec. 4-7, 2004, San Diego, CA Abstract #1482.
`Eisen et al., 2000, "Continuous low dose Thalidomide: a phase II
`study in advanced melanoma, renal cell, ovarian and breast cancer.”
`Br. J. Cancer 82(4):812-817.
`Fakhouri et al., 2004, “Thalidomide in patients with multiple
`myeloma and renal failure.” Br. J. Haematol. 125:90-102.
`Fenk et al., 2005, "Single-agent thalidomide for treatment of first
`relapse following high-dose chemotherapy in patients with multiple
`myeloma.” Leukemia 19(1): 156-159.
`Gupta et al., 2001, “Adherence of multiple myeloma cells to bone
`marrow stromal cells upregulates vascular endothelial growth factor
`secretion: therapeutic applications.” Leukemia 15(12): 1950-1961.
`Haslett et al., 2003, "Thalidomide and a thalidomide analogue drug
`costimulate virus-specific CD8+ T cells in vitro.” J. Infect. Dis.
`187(6):946-955.
`Hideshima et al., 2000, "Thalidomide and its analogs overcome drug
`resistance of human multiple myeloma cells to conventional
`therapy,” Blood 96(9):2943-2950.
`Offidani et al., 2003, Thalidomide plus oral melphalan for advanced
`multiple myeloma: a phase II study. Haematologica. Dec.
`2003;88(12): 1432-1433.
`Palumbo et al., 2004, "A prospective randomized trial of oral
`melphalan prednisone, thalidomide (MPT) vs. oral melphalan,
`prednisone (MP): An interim analysis.” Am. Soc. Hematol. 46' Ann.
`Meeting Dec. 4-7, 2004, San Diego, CA Abstract #207.
`Raje et al., 1999. “Thalidomide—a revival story.” N. Engl. J. Med.
`341 (21): 1606-1609.
`Rajkumar et al., 2004, “Thalidomide plus dexamethasone versus
`dexamethasone alone in newly diagnosed multiple myeloma
`(E1A00): Results of a phase III trial coordinated by the Eastern
`Cooperative Oncology Group.” Am. Soc. Hematol. 46' Ann. Meet
`ing Dec. 4-7, 2004, San Diego, CA Abstract #205.
`Rajkumar et al., 2000, "Prognostic value of bone marrow
`angiogenesis in multiple myeloma. Clin. Cancer Res. 6(8):31 11
`3116.
`Ribattietal., 1999, “Bone marrow angiogenesis and mast cell density
`increase simultaneously with progression of human multiple
`myeloma.” Br. J. Cancer 79(3-4):451-455.
`Singhal et al., 1999, Antitumor activity of thalidomide in refractory
`multiple myeloma, N. Engl. J. Med. 341 (21): 1565-1571.
`Steins et al., 2002, “Efficacy and safety of thalidomide in patients
`with acute myeloid leukemia.” Blood 99(3):834-839.
`
`ALVOGEN, Exh. 1001, p. 0002
`
`

`

`US 7,968,569 B2
`Page 3
`
`Vacca et al., 1999, “Bone marrow neovascularization, plasma cell
`angiogenic potential, and matrix metalloproteinase-2 secretion par
`allel progression of human multiple myeloma.” Blood 93(9):3064
`3073.
`Wohrer et al., 2004, “Effective treatment of primary plasma cell
`leukemia with thalidomide and dexamethasone—a case report.”
`Hematol. J. 5(4):361-363.
`N. Ake Jonnson, 1972, “Chemical Structure and Teratogenic Prop
`erties.” Acta Pharm., pp. 521-542.
`Anderson, “Moving disease biology from the laboratory to the
`clinic,” Seminars in Oncology, 200229:17-20.
`Barlogie et al., “Total Therapy II (TTII) for newly diagnosed multiple
`myeloma (MM): preliminary data on feasibility and efficacy in the
`first 231 enrolled patients; comparison with predecessor trial total
`therapy I ((TTI) (N=231).” Blood, Abstract #2857, Dec. 7-11, 2001,
`American Society of Hematology.
`Barlogie et al., “High-dose therapy immunomodulatory drugs in
`multiple myeloma.” Seminars in Oncology, 2002, 29 (6):26-33.
`Barlogie et al., “Introduction: Thalidomide and the IMiDs in multiple
`myeloma.” Seminars in Hematology, 2003, 40 (4): 1-2.
`Barlogie, “Thalidomide and CC-5013 in Multiple Myeloma: The
`University of Arkansas experience.” Seminars in Hematology, 2003,
`40 (4):33-38.
`Bartlettet al., “The evolution of thalidomide and its IMiD derivatives
`as anticancer agents.” Nature Reviews Cancer, 2004, 4 (4): 1-9.
`Bartlett et al., “Phase I study to determine the safety, tolerability and
`immunostimulatory activity of thalidomide analogue CC-5013 in
`patients with metastatic malignant melanoma and other advanced
`cancers.” British Journal of Cancer, 2004, 90:955-961.
`Battegay, "Angiogenesis: mechanistic insights, neovascular diseases,
`and therapeutic prospects.” J. Mol. Med., 1995, 73:333-346.
`Baz et al., “Doxil (D), vincristine (V), reduced frequency
`dexamethasone (d) and revlimid (R) (DVd-R) results in a high
`response rate inpatients with refractory multiple myeloma (RMM).”
`Blood, Abstract # 2559, American Society of Hematology, Dec.
`10-13, 2005.
`Brennen et al., “Thalidomide and analogues: current proposed
`mechanisms and therapeutic usage.” Clinical Prostate Cancer, 2004,
`3 (1):54-61.
`Celgene Corporation, “Celgene advances immunomodulatory drug
`(IMiDTM) clinical program.” Press Release, Feb. 2000.
`Celgene Corporation, “Initial Phase I solid tumor data on Celgene's
`lead ImiDTM, Revimid TM, Press Release, Jun. 2001.
`Celgene Corporation, “Celgene Corporation receives orphan drug
`designation for Revimidn't M for multiple myeloma.” Press Release,
`Oct. 2001.
`Celgene Corporation, “Celgene Corporation announces third quarter
`results. Thalomid(R) (thalidomide) sales increase 24%. Prescriptions
`up 50%. Enhanced S.T.E.P.S.(R) launched. Pilot d-MPH data pre
`sented.” Press Release, Oct. 2001.
`Celgene Corporation, “Celgene expands clinical development pro
`gram for Revimid TM —Five additional trials of Revimid initiated in
`hematological and solid tumor cancers.” Press Release, Jun. 2002.
`Celgene Corporation, “Celgene Corporation announces third quarter
`results. THALOMID(R) (thalidomide) revenue increases 41% to
`$30.5 million. Pivotal programs for THALOMID and REVIMIDTM
`finalized. Peer-reviewed publications of THALOMID and
`REVIMID data. First JNK inhibitor advanced to Phase I clinical
`trial. Press Release, Oct. 2002.
`Celgene Corporation, “Blood reports Revimid TM has anti-tumor
`activity in patients with relapsed and refractory multiple myeloma.”
`Press Release, Nov. 1, 2002.
`Celgene Corporation, "Celgene provides update on clinical pipeline.
`Celgene Announces first target indication for ACTIMIDTM,
`CC-8490. SelCIDTM program to advance based on results from Phase
`III trial of CC-1088. First JNK inhibitor successfully completes
`phase I trial.” Press Release, Jan. 2003.
`Celgene Corporation, “Celgene Corporation announces fourth quar
`ter and full year results for 2002.” Press Release, Jan. 2003.
`Celgene Corporation, “Celgene receives fast track status from FDA
`for Revimid TM in multiple myloma.” Press Release, Feb. 2003.
`
`Celgene Corporation, “Celgene receives fast track status from FDA
`for Revimid TM in myelodysplastic Sydromes.” Press Release, Apr.
`2003.
`Celgene Corporation, “New Revimid TM clinical data shows potential
`as novel approach to treating myelodysplastic syndromes (MDS).
`Press Release, May 2003.
`Celgene Corporation, “Celgene corporation reports strong operating
`performance in second quarter as total sales increase 100 percent and
`profits rise.” Press Release, Jul. 2003.
`Celgene Corporation, “Celgene corporation reports record operating
`performance in third quarter as total revenue increases 117% and
`profits rise.” Press Release, Oct. 2003.
`Celgene Corporation, “Celgene corporation advances ACTIMIDTM
`(CC-4047) into phase II trial for prostate cancer.” Press Release, Oct.
`2003.
`Celgene Corporation, "Additional clinical data presented on
`Revimid TM in myelodysplastic Sydromes at the American Society of
`Hematology 45" annual meeting.” Press Release, Dec. 2003.
`Celgene Corporation, “Celgene corporation reviews 2003 achieve
`ments and announces 2004 financial outlook.” Press Release, Jan.
`2004.
`Celgene Corporation, “Revlimid TM receives orphan drug designation
`from the European commission for multiple myeloma.” Press
`Release, Feb. 2004.
`Celgene Corporation, “Revlimid TM receives orphan drug designation
`from the European commission for myelodysplastic Sydromes.”
`Press Release, Mar. 2004.
`Celgene Corporation, “Celgene corporation reports record operating
`performance in first quarter with strong revenue growth and profits.”
`Press Release, Apr. 2004.
`Celgene Corporation, “Celgene announces plans to stop phase III
`trials in melanoma due to lack of efficacy.” Press Release, Apr. 2004.
`Dalgleish, et al., “New thalidomide analogues; anti-cancer, anti
`angiogenic and immunostimulatory.” British Journal of Cancer,
`2001, 85 (1)25.
`Dalgleish et al., “Thalidomide analogues CC-5013 and CC-4047
`induce T cell activation and IL-12 production in patients with both
`solid tumours and relapsed and refractory multiple myeloma.” British
`Journal of Cancer, 2003, 88(Suppl I), S25-S54.
`Database Pharmaml XPO02369094 retrieved from STN. Database
`accession No. 1659300, & Marketletter, Oct. 9, 2001.
`Database NLDBXPO02369095 retrieved from STN. Database acces
`sion No. 2002:35280, & Marketletter, Jun. 18, 2001.
`Davies et al., “Thalidomide (Thal) and immunomodulatory deriva
`tives (IMiDs) augment natural killer (NK) cell cytotoxicity in mul
`tiple myeloma(MM)).” Abstract #3617. American Society of Hema
`tology, Dec. 1-5, 2000.
`Davies et al., “Thalidomide (Thal) and immunomodulatory deriva
`tives (IMiDs) augment natural killer (NK) cell cytotoxicity in mul
`tiple myeloma -MM).” Abstract # P222, VIIIth International
`Myeloma Workshop, May 4-8, 2001.
`Dibbs et al., “Thalidomide and thalidomide analogs suppress TNFO.
`secretion by myocytes.” Abstract # 1284, Circulation, 1998.
`Dimopoulos et al., “Results of thalidomide and IMIDs in multiple
`myeloma”. Abstract i P12.1.4, International Multiple Myeloma
`Workshop, May 23-27, 2003.
`Dimopoulos et al., “Treatment of plasma cell dyscrasias with
`thalidomide and its derivatives,” Journal of Clinical Oncology, Dec.
`1, 2003, 21 (23)4444-4454.
`Dimopoulos et al., “Study of lenalidomide plus dexamethasonever
`sus dexamethasone alone in relapsed or refractory multiple myeloma
`(MM): Results of a phase 3 Study (MM-010).”. Abstract # 6, Ameri
`can Society of Hematology, Dec. 10-13, 2005.
`Dredge et al. A costimulatory thalidomide analog enhances the par
`tial anti-tumor immunity of an autologous vaccination in a model of
`colorectal cancer, Abstract # 491, American Association for Cancer
`Research, Apr. 6-10, 2002.
`Dredge et al., “Adjuvants and the promotion of Th1-type cytokines in
`tumour immunotherapy,” Cancer Immunol. Immunother, 2002,
`51:521-531.
`Dredge et al., “Immunological effects of thalidomide and its chemi
`cal and functional analogs.” Critical Reviews in Immunology, 2002,
`21 (5&6):425-437.
`
`ALVOGEN, Exh. 1001, p. 0003
`
`

`

`US 7,968,569 B2
`Page 4
`
`Dredge et al., “Protective antitumor immunity induced by a
`costimulatory thalidomide analog in conjunction with whole tumor
`cell vaccination is mediated by increased Th1 -type immunity'.” The
`Journal of Immunology, 2002, 168:4914-4919.
`Dredge et al., “Recent developments in antiangiogenic therapy.”
`Expert Opin. Biol. Ther. 2002, 2 (8):953-966.
`Dredge et al., “Angiogenesis inhibitors in cancer therapy. Current
`Opinion in Investigational Drugs, 2003, 4 (6):667-674.
`Dredge et al., “Thalidomide analogs as emerging anti-cancer drugs.”
`Anti-Cancer Drugs, 2003, 14:331-335.
`Fickentscher et al., “Stereochemical properties and teratogenic activ
`ity of some tetrahydrophthalimides.” Molecular Pharmacology,
`1976, 13:133-141.
`Figg et al., “Inhibition of angiogenesis: treatment options for patients
`with metastatic prostate cancer.” Investigational New Drugs, 2002,
`20(2): 183-194.
`Galustian et al., “Thalidomide-derived immunomodulatory drugs as
`therapeutic agents.” Expert Opin. Biol. Ther. 2004, 4 (12): 1-8.
`Glaspy et al., “The potential role of thalidomide and thalidomide
`analogs in melanoma. Clinical Advances in Hematology & Oncol
`ogy, 2004. 1-7.
`Gupta et al., “Adherence of multiple myeloma cells to bone marrow
`Stromal cells upregulates vascular endothelial growth factor Secre
`tion: therapeutic applications.” Leukemia, 2001, 15:1950-1961.
`Hayashi et al., “Mechanisms whereby immunomodulatory analogs
`of thalidomide augment autologous NK cell anti-myeloma immu
`nity.” Blood Abstract #3219, Dec. 6-10, 2002, American Society of
`Hematology.
`He, W., et al., 1993, Abstract of papers, 206th American Chemical
`Society, Chicago, IL; Med. Chem... paper 216.
`Helmet al., “Comparative teratological investigation of compounds
`of structurally and pharmacologically related to thalidomide.”
`Arzneimittel Forschung/Drug Research, 1981, 31 (I)941-949.
`Hernandez-Illizaliturret al., “Addition of immunomodulatory drugs
`CC5013 or CC4047 to rituximab enhances anti-tumor activity in a
`severe combined immunodeficiency (SCID) mouse lymphoma
`model.” Abstract #235, American Society of Hematology, Dec. 6-9,
`2003.
`Hideshima et al., “Thalidomide and its analogs overcome drug resis
`tance of human multiple myeloma cells to conventional therapy.”
`Blood, 2000, 96:2943-2950, American Society of Hematology.
`Hideshima et al., “Thalidomide (Thal) and its analogs overcome drug
`resistance of human multiple myeloma (MM) cells to conventional
`therapy.” Abstract 1313. American Society of Hematology, Dec. 1-5,
`2000.
`Hunt et al., “Markers of endothelial and haemostatic activation in the
`use of CC-4047, a structural analogue of thalidamide, in relapsed
`myeloma.” Blood Abstract #3216, Dec. 6-10, 2002, American Soci
`ety of Hematology.
`Hussein et al., “Doxil (D), vincristine (V), reduced frequency
`dexamethasone (d) and Revlimid (DVd-R) a phase I/II trial in
`advanced relapsed/refractory multiple myeloma (Rmm) patients.”
`Blood, Abstract #208, American Society of Hematology, Dec. 4-7.
`2004.
`Hwu et al., “Thalidomide and its analogues in the treatment of meta
`static melanoma.” Chemotherapy Foundation Symposium, Abstract
`#44, 2002.
`Kyle, "Current therapy of multiple myeloma.” Internal Medicine,
`2002, 41 (3) 175-180.
`Kyle et al., “Multiple myeloma.” New England Journal of Medicine,
`2004, 351:1860-1873.
`LeBlanc et al., “Immunomodulatory drug costimulates T cells via the
`B7-CD28 pathway,” Blood, 2004, 103: 1787-1790, American Society
`of Hematology.
`Lentzsch et al., “In vivo activity of thalidomide and immunomodula
`tory drugs against multiple myeloma.” VIIIth International Myeloma
`Workshop. Abstract #P225, May 4-8, 2001.
`Lentzsch et al., “Immunomodulatory derivative of thalidomide
`(IMiD CC-4047) determine the lineage commitment of
`hematopoietic progenitors by down regulation of GATA-1 and modu
`lation of cytokine secretion.” Abstract # 3073, American Society of
`Hematology, Dec. 6-9, 2003.
`
`Lentzsch et al., “Immunomodulatory derivative of thalidomide
`(IMiD CC-4047) down regulates CAAT/enhancer-binding protein
`P(C/EBPP) in multiple myeloma (MM).” Abstract # 3456, American
`Society of Hematology, Dec. 6-9, 2003.
`Luzzio et al., “Thalidomide analogues: derivatives of an orphan drug
`with diversebiological activity.” Expert Opin. Ther. Patents, 2004, 14
`(2):215-229.
`Man et al., “O- Fluoro-substituted thalidomide analogues.”
`Bioorganic & Medicinal Chemistry Letters 13, 2003, 3415-3417.
`Marriott et al., “Immunotherapeutic and antitumour potential of
`thalidomide analogues.” Expert Opin. Biol. Ther. 2001, 1 (4): 1-8.
`Marriott et al., “New thalidomide analogues; anti-cancer, anti
`angiogenic and immunostimulatory.” British Journal of Cancer,
`85:25, Jul. 6, 2001.
`Marriott et al., “Thalidomide and its analogues have distinct and
`opposing effects on TNF-C. and TNFR2 during co-stimulation of both
`CD4"and CD8"T cells.” Clin. Exp. Immunol., 2002, 130:75-84.
`Marriott et al., “A novel subclass of thalidomide analogue with anti
`Solid tumor activity in which caspase-dependent apoptosis is associ
`ated with altered expression of bcl-2 family proteins.” Cancer
`Research, 2003, 63:593-599.
`Marriott et al., “Thalidomide derived immunomodulatory drugs
`(IMiDs) as potential therapeutic agents. Current Drug Targets—
`Immune. Endocrine & Metabolic Disorders, 2003, 3:181-186.
`Masellis et al., “Changes in gene expression in bone marrow
`mesenchymal progenitor cells as a consequence of IMiD therapy in
`multiple myelomapatients.” Blood, Abstract #1548, Dec. 7-11, 2001,
`American Society of Hematology.
`McCarty, “Thalidomide may impede cell migration in primates by
`down-regulating integrin f3-chains: potential therapeutic utility in
`Solid malignancies, proliferative retinopathy, inflammatory disor
`ders, neointimal hyperplasia, and osteoporosis.” Medical Hypoth
`eses, 1997, 49:123-131.
`Mitsiades et al., "Apoptic signaling induced by immunomodulatory
`thalidomide analogs (Imids) in human multiple myeloma cells: thera
`peutic implications.” Abstract # 3224. Dec. 7-11, 2001, American
`Society of Hematology.
`Mitsiades et al., “Apoptic signaling induced by immunomodulatory
`thalidomide analogs in human multiple myeloma cells: therapeutic
`implications.” Blood, 2002, 99:4525-4530, American Society of
`Hematology.
`Mitsiades et al., "CC-5013 Celgene.” Current Opinion in Investiga
`tional Drugs, 2004, 5 (6):635-647.
`Moutouh et al., “Novel immunomodulatory drugs (IMiDR): Apoten
`tial, new therapy for B- hemoglobinopathies.” Abstract # 3740,
`American Society of Hematology, Dec. 4-7, 2004.
`Patten et al., “The early use of the serum free light chain assay in
`patients with relapsed refractory myeloma receiving treatment with a
`thalidomide analogue (CC-4047).” Abstract # 1640, American Soci
`ety of Hematology, Dec. 6-9, 2003.
`Payvandiet al., “Effects of a thalidomide analog on binding activity
`of transcription factors and cell cycle progression of multiple
`myeloma cell lines.” Blood Abstract #2487. Dec. 1-5, 200, American
`Society of Hematology.
`Payvandiet al., “The thalidomide analogs IMiDs enhance expression
`of CD69 stimulatory receptor on natural killer cells.” Abstract #
`1793, American Association for Cancer Research, Mar. 24-28, 2001.
`Payvandi et al., “Thaliomide analogs IMiDs inhibit expression of
`cyclooxygenase-2 in multiple myeloma cell line and LPS stimulated
`PBMCs.” Blood, Abstract # 2689, Dec. 7-11, 2001, American Society
`of Hematology.
`Payvandiet al., “Thalidomide and IMiDS inhibit microvessel forma
`tion from human arterial rings in the absence of human liver
`microsomes.” Blood, Abstract #5046, Dec. 6-10, 2002, American
`Society of Hematology.
`Payvandi et al., "CC-5013 inhibits the expression of adhesion mol
`ecules ICAM-1 and CD44 and prevents metastasis of B16 F10 mouse
`melanoma cells in an animal model.” American Society of Clinical
`Oncology, Abstract # 992, 2003.
`Payvandi et al., “Immunomodulatory drugs inhibit expression of
`cyclooxygenase-2 from TNF-O, IL-1B, and LPS-stimulated stimu
`lated human PMBC in apartially IL-10-dependent manner.” Cellular
`Immunology, 2004, 81-88.
`
`ALVOGEN, Exh. 1001, p. 0004
`
`

`

`US 7,968,569 B2
`Page 5
`
`Raje et al., “Combination of the mTOR inhibitor rapamycin and
`CC-5013 has synergistic activity in multiple myeloma.” Blood, Dec.
`15, 2004, 104 (13)418.8-4.193.
`Rajkumar et al., “Combination therapy with lenalidomide plus
`dexamethasone (Rev. Dex) for newly diagnosed myeloma.” Blood,
`Dec. 15, 2005, 106 (13)4050-4053.
`Richardson et al., “A Phase 1 study of oral CC5013, an
`immunomodulatory thalidomide (Thal) derivative, in patients with
`relapsed and refractory multiple myeloma (MM).” Blood Abstract
`#3225. Dec. 7-11, 2001, American Society of Hematology.
`Richardson et al., “Immunomodulatory drug CC-5013 overcomes
`drug resistance and is well tolerated in patients with relapsed multiple
`myeloma.” Blood, 2002 100:3063-3067, American Society of Hema
`tology.
`Richardson et al., “A multi-center, randomized, phase 2 study to
`evaluate the efficacy and safety of 2 CDC-5013 dose regimens when
`used alone or in combination with dexamethasone (Dex) for the
`treatment of relapsed or refractory multiple myeloma (MM).” Blood,
`Abstract # 825, American Society of Hematology, Dec. 6-9, 2003.
`Richardson et al., “Immunomodulatory analogs of thalidomide: an
`emerging new therapy in myeloma.” Journal of Clinical Oncology,
`2004, 22(16) 32 12-3214.
`Richardson et al., “A multicenter, single-arm, open-label study to
`evaluate the efficacy and Safety of single-agent lenalidomide in
`patients with relapsed and refractory multiple myeloma; preliminary
`results.” 10" International Myeloma Workshop, Apr. 10-14, 2005.
`Richardson et al., “Novel biological therapies for the treatment of
`multiple myeloma.” Best Practice & Research Clinical Haematol
`ogy, 2005, 18 (4):619-634.
`Richardson et al., “A phase 1 trial of lenalidomide (REVLIMID(R).)
`with bortezomib (VELCADE(R) in relapsed and refractory multiple
`myeloma.” Blood, Abstract # 365, American Society of Hematology,
`Dec. 10-13, 2005.
`Rubinet al., “Principles of cancer treatment-1.” 2003, 12 ONCO IV
`1.
`Schafer et al., “Enhancement of cytokine production and AP-1 tran
`Scriptional activity in T cells by thalidomide-related immunomodula
`tory drugs.” Journal of Pharmacology and Experimental Therapeu
`tics, 2003, 305(3) 1222-1232.
`Schey et al., “A phase I study of an immunomodulatory thalidomide
`analog, CC-4047, in relapsed or refractory multiple myeloma.” Jour
`nal of Clinical Oncology, 2004, 22 (16): 1-8.
`Schey et al., “A phase I study of an immunomodulatory thalidomide
`analogue (CC4047) in relapse/refractory multiple myeloma.” Inter
`national Society for Experimental Hematology, Abstract #248, 2002.
`Shaughnessy et al., “Global gene expression analysis shows loss of
`C-MYC and IL-6 receptor gene mRNA after exposure of myelomato
`thalidomide and IMiD.” Abstract # 2485. The American Society of
`Hematology, Dec. 1-5, 2000.
`Shire et al., “TNF-C. inhibitors and rheumatoid arthritis.” Exp. Opin.
`Ther: Patents, 1998, 8 (5):531-544.
`Sorbbera et al., "CC-5013. Treatment of multiple myeloma. Treat
`ment of Melanoma. Treatment of myelodysplastic syndrome.
`Angiogenesis inhibitor. TNF-C. production inhibitor.” Drugs of the
`Future, 2003, 28(5):425-431.
`Streetly et al., “Thalidomide analogue CC-4047 is effective in the
`treatment of patients with relapsed and refractory multiple myeloma
`(MM) and induces T-cell activation and IL-12 production.” Abstract
`#367, International Multiple Myeloma Workshop, May 23-27, 2003.
`Streetly et al., “Changes in neutrophil phenotype following the
`administration of CC-4047 (Actimid) to patients with multiple
`myeloma.” Abstract # 2543, American Society of Hematology, Dec.
`6-9, 2003.
`Streetly et al., “An update of the use and outcomes of the new
`immunomodulatory agent CC-4047 (Actimid) in patients with
`relapsed/refractory myeloma.” Abstract #829, American Society of
`Hematology, Dec. 6-9, 2003.
`Teo et al., “A phase I, single-blind, placebo-controlled, ascending
`single oral dose, Safety, tolerability and pharmacokinetic study of
`CDC-501, a novel immunomodulat